Bacterial Infection Clinical Trial
Official title:
Postoperative Antibiotic Requirements Following Immediate Breast Reconstruction
Verified date | May 2014 |
Source | Stony Brook University |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
Antibiotics are used routinely in postoperative tissue expander based breast reconstruction
(TE) and autologous flap (AF) breast reconstruction procedures. Closed suction drains are
also used routinely in immediate breast reconstruction to prevent fluid accumulation and
seroma formation at the surgical sites. Antibiotics are most often prescribed as a
precaution since drains can be a source for infection by creating open channels to outside
contaminants. Plastic surgery patients without closed suction drainage devices are usually
not placed on prolonged postoperative antibiotics. Current preoperative surgical antibiotic
prophylaxis is recommended for up to 24 hours only. These recommendations do not take into
account the increased risk of indwelling closed suction drains. A recent survey of plastic
surgeons, conducted by SBUMC investigators, (IRB# 129415) found that Plastic Surgeons are
divided as to extended outpatient administration following TE breast reconstruction.
The study plans to prospectively enroll patients who will undergo immediate breast
reconstruction with TE or AF based breast reconstruction. Using the above data and the
current protocol, the investigators will investigate the optimal antibiotic discontinuation
period for these patients. The investigators hypothesize that the use of 24-hour
perioperative antibiotics in TE or AF based immediate breast reconstruction with closed
suction drainage, does not result in an increased infection rate compared to prolonged
postoperative antibiotic administration.
Status | Completed |
Enrollment | 132 |
Est. completion date | May 2014 |
Est. primary completion date | May 2014 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - All patients presenting to Stony Brook University Medical Center Plastic Surgery clinic for immediate breast reconstruction using a tissue expander. - Age 18 years or older Exclusion Criteria - Delayed or revision implant reconstruction - Refusal or inability to consent - Contraindications to surgery as determined by attending physician - Contraindications to both penicillin/cephalosporin and clindamycin antibiotics (significant allergies) - Patients with serious existing systemic infection, defined as 2 or more of the following: Peripheral body temperature >38 degrees Celsius CRP >5g/L Leukocytes > 12,000/microliter |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Stony Brook University Medical Center | Stony Brook | New York |
Lead Sponsor | Collaborator |
---|---|
Stony Brook University | Plastic Surgery Educational Foundation |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Surgical Site infection | One or more of the following: Purulent drainage, with or without laboratory confirmation, from the superficial incision. Organisms isolated from an aseptically obtained culture of fluid or tissue from the superficial incision. At least one of the following signs or symptoms of infection: pain or tenderness, localized swelling, redness, or heat and superficial incision is deliberately opened by surgeon, unless incision is culture-negative. Diagnosis of superficial incisional SSI by the surgeon or attending physician. |
365 days after the procedure | Yes |
Secondary | Antibiotic Sensitivity | Assessed by documentation of an allergic or adverse sensitivity reaction including, but not limited to urticaria, itching, rash, anaphylaxis | From administration of the antibiotic until discontinuation | Yes |
Secondary | Clostridium Difficile Colitis | C. Difficile colitis will be assessed by documented positive c. difficile toxin assay. | up to 365 days postoperatively | Yes |
Secondary | Antibiotic Resistance | Local wound infections will be cultured and sent for identification and susceptibility. Alternatively, pathological fluid collections will be aspirated and fluid will be sent for culture and susceptibility. Resistant strains will be documented and treated with alternative antibiotics. | 1 year postoperatively | Yes |
Secondary | Patient compliance | patients will be asked to bring antibiotics to clinic for counting to assess compliance. | while antibiotics are being administered postoperatively | No |
Secondary | Cost | Cost will be assessed by multiplying the duration of outpatient postoperative antibiotics by the cost for self-pay prescriptions. | while antibiotics are being administered postoperatively | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02794831 -
Exposure to NSAIDs (Non Steroidal Anti-Inflammatory Drugs) and Severity of Community-acquired Bacterial Infections
|
||
Active, not recruiting |
NCT02533609 -
Elimination of Antibiotics During Citrate-anticoagulated Continuous-veno-venous-haemodialysis
|
||
Completed |
NCT01892358 -
Preventing Bacterial and Viral Infections Among Injection Drug Users
|
N/A | |
Completed |
NCT01446289 -
Immune Response Induced by a Vaccine Against Group B Streptococcus and Safety in Pregnant Women and Their Offsprings
|
Phase 2 | |
Completed |
NCT01371656 -
Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation
|
Phase 3 | |
Completed |
NCT01059890 -
Cerebral Antibiotics Distribution After Acute Brain Injury
|
Phase 1 | |
Completed |
NCT00389558 -
Antiseptic Use and Dressing Application
|
Phase 4 | |
Completed |
NCT00760279 -
An Open Label Evaluation of the Pharmacokinetics and Safety of Single Dose Intravenous Azithromycin in Preterm Neonates
|
Phase 1 | |
Completed |
NCT02311816 -
Increase in Procalcitonin Kinetics May be a Good Indicator of Starting Empirical Antibiotic Treatment in Critically Ill Patients
|
N/A | |
Completed |
NCT01225042 -
The Effect of Probiotics on E. Coli Gastroenteritis
|
N/A | |
Completed |
NCT00800488 -
Procalcitonin for Predicting Serious Bacterial Infection in Infants Less Than 3 Months
|
N/A | |
Completed |
NCT00915213 -
Incidence of Antibiotic Resistant E.Coli in Patients Undergoing Repeat Prostate Biopsy
|
N/A | |
Not yet recruiting |
NCT00765778 -
Mastering Hospital Antimicrobial Resistance and Its Spread Into the Community
|
N/A | |
Terminated |
NCT00307099 -
Comparative Antibiotic Therapy for Subjects With Pulmonary Infiltrates in the ICU
|
Phase 3 | |
Recruiting |
NCT04479657 -
Qingfei Granule for the Treatment of the Pediatric Acute Upper Respiratory Tract Infection With Bacterial Infection
|
Early Phase 1 | |
Completed |
NCT03299894 -
Impact of qSOFA Calculation on the Timing of Antimicrobial Therapy in the Emergency Department
|
N/A | |
Completed |
NCT01817075 -
Chlorhexidine Gluconate Cleansing in Preventing Central Line Associated Bloodstream Infection and Acquisition of Multi-drug Resistant Organisms in Younger Patients With Cancer or Undergoing Donor Stem Cell Transplant
|
Phase 3 | |
Completed |
NCT01250574 -
Neutrophil CD64 and Procalcitonin as Novel Biomarkers for Postoperative Infections
|
||
Completed |
NCT01012089 -
Study of the Pharmacokinetics of Daptomycin in Children With Renal Disease
|
N/A | |
Withdrawn |
NCT00430469 -
Safety of hLF1-11 for the Treatment of Infectious Complications Among HSCT Recipients
|
Phase 1/Phase 2 |